Literature DB >> 18990163

Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.

Mesut Remzi1, Andrea Haitel, Vitaly Margulis, Pierre Karakiewicz, Pierre Karakiewizc, Francesco Montorsi, Eiji Kikuchi, Richard Zigeuner, Alon Weizer, Christian Bolenz, Karim Bensalah, Nazareno Suardi, Jay D Raman, Yair Lotan, Matthias Waldert, Casey K Ng, Mario Fernández, Theresa M Koppie, Philipp Ströbel, Wareef Kabbani, Masaru Murai, Cord Langner, Marco Roscigno, Jeffrey Wheat, Charles C Guo, Christopher G Wood, Shahrokh F Shariat.   

Abstract

OBJECTIVE: To assess whether tumour architecture can help to refine the prognosis of patients treated with nephroureterectomy (NU) for urothelial carcinoma (UC) of the upper urinary tract (UT), as the prognostic value of tumour architecture (papillary vs sessile) in UTUC remains elusive. PATIENTS AND METHODS: The study included 1363 patients with UTUC and treated with radical NU at 12 centres worldwide. All slides were re-reviewed according to strict criteria by genitourinary pathologists who were unaware of the findings of the original pathology slides and clinical outcomes. Gross tumour architecture was categorized as sessile vs papillary.
RESULTS: Papillary growth was identified in 983 patients (72.2%) and sessile growth in 380 (27.8%). The sessile growth pattern was associated with higher tumour grade, more advanced stage, lymphovascular invasion, and metastasis to lymph nodes (all P < 0.001). In multivariable Cox regression analyses that adjusted for the effects of pathological stage, grade and lymph node status, tumour architecture (sessile or papillary) was an independent predictor of cancer recurrence (hazard ratio 1.5, P = 0.002) and cancer-specific mortality (1.6, P = 0.001). Adding tumour architecture increased the predictive accuracy of a model that comprised pathological stage, grade and lymph node status for predicting cancer recurrence and cancer-specific death by a minimal but statistically significant margin (gain in predictive accuracy 1% and 0.5%, both P < 0.001).
CONCLUSION: The tumour architecture of UTUC is associated with established features of biologically aggressive disease, and more importantly, with prognosis after radical NU. Including tumour architecture in predictive models for disease progression should be considered, aiming to identify patients who might benefit from early systemic therapeutic intervention.

Entities:  

Mesh:

Year:  2008        PMID: 18990163     DOI: 10.1111/j.1464-410X.2008.08003.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  46 in total

1.  Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.

Authors:  Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

2.  [Urothelial carcinoma of the upper urinary tract: clinical and pathological criteria and their predictive implications after radical nephroureterectomy].

Authors:  Christian Seitz; Paul Schramek
Journal:  Wien Med Wochenschr       Date:  2011-08

Review 3.  [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].

Authors:  M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

Review 4.  Expression of p53 in upper urinary tract urothelial carcinoma.

Authors:  Stephen Mitchell; Erik Mayer; Anup Patel
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

5.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 6.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.

Authors:  Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

Review 7.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

8.  Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.

Authors:  Sima Porten; Arlene O Siefker-Radtke; Lianchun Xiao; Vitaly Margulis; Ashish M Kamat; Christopher G Wood; Eric Jonasch; Colin P N Dinney; Surena F Matin
Journal:  Cancer       Date:  2014-03-13       Impact factor: 6.860

9.  Risk of cancer-specific mortality following recurrence after radical nephroureterectomy.

Authors:  Michael Rink; Daniel Sjoberg; Evi Comploj; Vitaly Margulis; Evanguelos Xylinas; Richard K Lee; Jens Hansen; Eugene K Cha; Jay D Raman; Mesut Remzi; Karim Bensalah; Giacomo Novara; Surena F Matin; Felix K Chun; Eiji Kikuchi; Wassim Kassouf; Juan I Martinez-Salamanca; Yair Lotan; Christian Seitz; Armin Pycha; Richard Zigeuner; Pierre I Karakiewicz; Douglas S Scherr; Andrew J Vickers; Shahrokh F Shariat
Journal:  Ann Surg Oncol       Date:  2012-07-18       Impact factor: 5.344

10.  Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.

Authors:  Michael Rink; Evanguelos Xylinas; Vitaly Margulis; Eugene K Cha; Behfar Ehdaie; Jay D Raman; Felix K Chun; Kazumasa Matsumoto; Yair Lotan; Helena Furberg; Marek Babjuk; Armin Pycha; Christopher G Wood; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2012-06-22       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.